Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 21 studies | 30% ± 13% | |
| oligodendrocyte | 16 studies | 48% ± 16% | |
| astrocyte | 13 studies | 31% ± 14% | |
| macrophage | 12 studies | 32% ± 15% | |
| classical monocyte | 11 studies | 25% ± 10% | |
| glutamatergic neuron | 11 studies | 44% ± 26% | |
| GABAergic neuron | 10 studies | 38% ± 23% | |
| microglial cell | 10 studies | 30% ± 10% | |
| oligodendrocyte precursor cell | 10 studies | 32% ± 13% | |
| myeloid cell | 8 studies | 26% ± 7% | |
| epithelial cell | 8 studies | 33% ± 10% | |
| monocyte | 7 studies | 29% ± 10% | |
| pericyte | 7 studies | 23% ± 9% | |
| dendritic cell | 7 studies | 30% ± 8% | |
| neuron | 6 studies | 33% ± 18% | |
| interneuron | 6 studies | 43% ± 23% | |
| fibroblast | 6 studies | 26% ± 8% | |
| type I pneumocyte | 6 studies | 23% ± 10% | |
| adipocyte | 5 studies | 21% ± 3% | |
| mast cell | 5 studies | 23% ± 6% | |
| endothelial cell of lymphatic vessel | 5 studies | 30% ± 8% | |
| non-classical monocyte | 4 studies | 25% ± 9% | |
| granule cell | 4 studies | 29% ± 6% | |
| retinal ganglion cell | 4 studies | 37% ± 15% | |
| basal cell | 4 studies | 30% ± 13% | |
| lymphocyte | 4 studies | 23% ± 9% | |
| amacrine cell | 4 studies | 31% ± 8% | |
| retina horizontal cell | 4 studies | 23% ± 8% | |
| smooth muscle cell | 4 studies | 25% ± 1% | |
| hematopoietic precursor cell | 3 studies | 33% ± 16% | |
| GABAergic interneuron | 3 studies | 30% ± 5% | |
| glial cell | 3 studies | 20% ± 4% | |
| endothelial cell of artery | 3 studies | 17% ± 1% | |
| mononuclear phagocyte | 3 studies | 26% ± 6% | |
| vein endothelial cell | 3 studies | 37% ± 27% | |
| ciliated cell | 3 studies | 24% ± 1% | |
| GABAergic amacrine cell | 3 studies | 31% ± 14% | |
| ON-bipolar cell | 3 studies | 23% ± 10% | |
| glycinergic amacrine cell | 3 studies | 27% ± 8% | |
| retinal rod cell | 3 studies | 20% ± 3% | |
| rod bipolar cell | 3 studies | 27% ± 11% | |
| natural killer cell | 3 studies | 20% ± 3% | |
| alveolar macrophage | 3 studies | 36% ± 11% | |
| transit amplifying cell | 3 studies | 37% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 7211.70 | 1445 / 1445 | 100% | 60.48 | 183 / 183 |
| prostate | 100% | 4609.67 | 245 / 245 | 100% | 28.16 | 500 / 502 |
| lung | 100% | 5173.24 | 577 / 578 | 100% | 33.98 | 1152 / 1155 |
| brain | 100% | 4997.45 | 2629 / 2642 | 100% | 34.21 | 705 / 705 |
| pancreas | 100% | 3121.53 | 328 / 328 | 99% | 31.02 | 177 / 178 |
| uterus | 100% | 6807.38 | 170 / 170 | 99% | 35.65 | 456 / 459 |
| bladder | 100% | 5280.71 | 21 / 21 | 99% | 31.55 | 499 / 504 |
| thymus | 100% | 4603.24 | 652 / 653 | 99% | 20.41 | 598 / 605 |
| breast | 100% | 4847.85 | 459 / 459 | 98% | 39.52 | 1100 / 1118 |
| intestine | 100% | 5489.38 | 966 / 966 | 98% | 33.31 | 516 / 527 |
| stomach | 100% | 6584.52 | 359 / 359 | 98% | 37.33 | 280 / 286 |
| ovary | 100% | 5191.28 | 180 / 180 | 97% | 17.30 | 418 / 430 |
| kidney | 100% | 2831.87 | 89 / 89 | 97% | 21.78 | 875 / 901 |
| adrenal gland | 100% | 3236.01 | 258 / 258 | 94% | 17.89 | 217 / 230 |
| skin | 99% | 3477.78 | 1784 / 1809 | 89% | 21.71 | 418 / 472 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 19.64 | 29 / 29 |
| spleen | 100% | 4622.81 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 45.61 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 22.58 | 1 / 1 |
| adipose | 100% | 4928.76 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 4706.87 | 1333 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 99% | 2244.96 | 794 / 803 | 0% | 0 | 0 / 0 |
| heart | 98% | 2998.72 | 846 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 88% | 3969.15 | 817 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 51% | 7.50 | 41 / 80 |
| liver | 8% | 87.62 | 17 / 226 | 16% | 2.57 | 65 / 406 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0008611 | Biological process | ether lipid biosynthetic process |
| GO_0010025 | Biological process | wax biosynthetic process |
| GO_0046474 | Biological process | glycerophospholipid biosynthetic process |
| GO_0035336 | Biological process | long-chain fatty-acyl-CoA metabolic process |
| GO_0005778 | Cellular component | peroxisomal membrane |
| GO_0005777 | Cellular component | peroxisome |
| GO_0102965 | Molecular function | alcohol-forming long-chain fatty acyl-CoA reductase activity |
| GO_0016491 | Molecular function | oxidoreductase activity |
| GO_0080019 | Molecular function | alcohol-forming very long-chain fatty acyl-CoA reductase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FAR1 |
| Protein name | Fatty acyl-CoA reductase 1 (EC 1.2.1.84) (Male sterility domain-containing protein 2) Fatty acyl-CoA reductase (EC 1.2.1.84) Fatty acyl-CoA reductase 1 |
| Synonyms | UNQ2423/PRO4981 MLSTD2 |
| Description | FUNCTION: Catalyzes the reduction of saturated and unsaturated C16 or C18 fatty acyl-CoA to fatty alcohols . It plays an essential role in the production of ether lipids/plasmalogens which synthesis requires fatty alcohols . In parallel, it is also required for wax monoesters production since fatty alcohols also constitute a substrate for their synthesis (By similarity). . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . FUNCTION: Catalyzes the reduction of fatty acyl-CoA to fatty alcohols. . |
| Accessions | Q8WVX9 ENST00000532701.1 A0A8V8TQT9 E9PNW8 ENST00000532502.1 E9PPB8 ENST00000354817.8 ENST00000703358.1 |